KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ:307750)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,040.00
+10.00 (0.25%)
At close: Sep 18, 2025

KUKJEON PHARMACEUTICAL Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
135,077136,468121,998103,71185,354
Other Revenue
-0-0---0
135,077136,468121,998103,71185,354
Revenue Growth (YoY)
1.35%11.86%17.63%21.51%-
Cost of Revenue
116,214114,59496,72184,19567,409
Gross Profit
18,86321,87425,27719,51517,946
Selling, General & Admin
14,90715,32712,81711,4518,699
Research & Development
4,0614,6844,8213,9812,651
Operating Expenses
21,20021,50718,76816,02711,836
Operating Income
-2,337366.716,5093,4886,109
Interest Expense
-7,136-8,220-5,735-1,802-284.47
Interest & Investment Income
300.38878.981,5911,037208.91
Earnings From Equity Investments
-146.08-57.481.15301.09-
Currency Exchange Gain (Loss)
276.31-1,655-253.67-1,215-869.65
Other Non Operating Income (Expenses)
8,98210,498-391.289,279196.4
EBT Excluding Unusual Items
-60.71,8111,72211,0895,360
Gain (Loss) on Sale of Investments
2,3131,83116.2867.84-275.98
Gain (Loss) on Sale of Assets
-49.07-57.43--69.18-0
Other Unusual Items
-3,637-2,706---
Pretax Income
-1,433879.321,73811,0885,084
Income Tax Expense
303.35341.65-2,9542,2101,046
Earnings From Continuing Operations
-1,737537.674,6928,8774,038
Minority Interest in Earnings
960.651,19913270.7-
Net Income
-776.191,7364,8248,9484,038
Net Income to Common
-776.191,7364,8248,9484,038
Net Income Growth
--64.01%-46.09%121.59%-
Shares Outstanding (Basic)
4949494944
Shares Outstanding (Diluted)
4949495144
Shares Change (YoY)
-9.13%--4.23%16.16%-
EPS (Basic)
-15.7335.3898.31182.3591.54
EPS (Diluted)
-15.7335.3898.3111.3591.00
EPS Growth
--64.01%766.11%-87.53%-
Free Cash Flow
1,0532,169-44,269-29,304-7,367
Free Cash Flow Per Share
21.3344.20-902.17-571.94-167.01
Dividend Per Share
10.00010.000---
Gross Margin
13.96%16.03%20.72%18.82%21.02%
Operating Margin
-1.73%0.27%5.33%3.36%7.16%
Profit Margin
-0.57%1.27%3.95%8.63%4.73%
Free Cash Flow Margin
0.78%1.59%-36.29%-28.26%-8.63%
EBITDA
2,9135,4729,6434,9327,215
EBITDA Margin
2.16%4.01%7.90%4.75%8.45%
D&A For EBITDA
5,2505,1053,1341,4441,106
EBIT
-2,337366.716,5093,4886,109
EBIT Margin
-1.73%0.27%5.33%3.36%7.16%
Effective Tax Rate
-38.85%-19.94%20.58%
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.